Novel Pharmacologic Treatments of Female Sexual Dysfunction.

This review paper evaluates pharmacologic treatments for female sexual dysfunction (FSD), with a primary focus on hypoactive sexual desire disorder (HSDD). The authors examine the two FDA-approved medications for FSD — flibanserin (a daily oral serotonin/dopamine modulator) and bremelanotide (an on-demand injectable melanocortin receptor agonist) — alongside investigational therapies such as Lorexys (a bupropion/trazodone combination) and various testosterone-based treatments. The review synthesizes study outcomes and safety profiles for each agent, and offers clinical guidance on patient selection, diagnosis, expectation setting, side effect management, and patient education. The authors note that while FDA-approved options exist, their clinical uptake has been limited by modest effect sizes, side effect burdens, and barriers to access. Investigational therapies show early promise but require further clinical validation. A key limitation of this paper is its nature as a narrative review, meaning it does not pool data systematically and may be subject to selection bias in the studies included. It does not introduce new primary data.

Why this grade: This is a narrative review article synthesizing existing literature and FDA-approved data; it generates no new primary clinical or experimental evidence of its own.